UK: UK Supreme Court Approves ‘Skinny Labelling'

Last Updated: 21 December 2018
Article by Philip French

The UK's highest court has held that patents directed towards new medical uses for known products must disclose some sound scientific reasoning or directly relevant experimental evidence in support of the claimed use. The test for infringement of such patents is likely to depend primarily on the objective appearance and presentation of an allegedly infringing product, and in particular whether the product is presented as suitable for the patented use. However a number of questions are left unanswered, and this judgment is unlikely to be the final word on the tricky issue of infringement of second medical use patents.

Court approves 'Skinny Labelling'

The UK Supreme Court has now ruled on the appeal in Warner-Lambert v Generics UK (trading as Mylan) and Actavis. The full judgement can be read here. The hearing was held in February 2018 and the Court's judgement has been eagerly awaited as it is the first time the concepts of sufficiency and infringement as applied to 2nd medical use claims have been considered in the UK's highest Court. The judgement is also the first concerning the common practice of so called 'skinny labelling'.

The case is concerned with Warner Lambert's product Lyrica ®(pregabalin) which is authorised for the treatment of peripheral neuropathic pain, central neuropathic pain, epilepsy, and generalised anxiety disorder (GAD). Its largest market is neuropathic pain. In the patent, Claim 1 is directed to the use in treating pain per se, Claim 2 is directed to inflammatory pain and Claim 3 is directed to neuropathic pain. In the proceedings, Warner-Lambert claimed against Actavis for infringement of Claims 1 and 3, Generics UK and Actavis had sought revocation of the patent.

Skinny Labelling

The Summary of Product Characteristics (SmPC) describes how to use a medicine which has obtained regulatory approval in Europe. The document includes a section listing the medical conditions for which the medicine is authorised for use. It is not unusual for several conditions to be listed and they can, condition by condition be covered by several different patents, and some conditions may be covered by no patent. It is standard practice for companies to make generic versions of drugs after the original compound patent has expired. Where a 2nd medical use patent is still in force, the SmPC on the generic product may be amended to remove the text relating to any patented use, and thus seek to avoid infringement. This is referred to as 'skinny labelling'. Usually the medical use removed is of low commercial value and the Patentee does not take any action against the company selling the generic version. In the case of pregabalin, the compound had previously been known as an anticonvulsant (and therefore used in the treatment of epilepsy), the patent in suit is a later patent filing directed to the use in pain, including neuropathic pain.

The issue, in the present case, is that neuropathic pain represents the largest commercial market for pregabalin. Therefore, Warner Lambert took legal action against Actavis for infringement of this second medical use patent, even though the neuropathic pain indication had been removed from Actavis's SmPC. Warner Lambert asserted that Actavis knew that their product would be used for neuropathic pain and therefore removing the text from the SmPC did not circumvent liability for the infringing activity.

Even though the Supreme Court ruled that the claims in suit are invalid for lack of sufficiency (see below) the Court went on to consider the infringement question. In the decision the Supreme Court considered both direct and indirect infringement.

With respect to direct infringement, the five membered Court, by a 4/1 majority decision ruled that, if the claims had been found sufficient, there would have been no infringement. Interestingly, the four Justices differed in their reasons for finding non-infringement. Lord Sumption, who wrote the leading judgement, and Lord Reed ruled that an 'outward presentation test' should be applied to the question of infringement, i.e. the intention of the alleged infringer was irrelevant and the sole criterion is whether the product, as it emerges from the manufacturing process, including any labelling, formulation, dosage or accompanying leaflet, is presented for the uses which enjoy patent protection. Lord Sumption, in his judgement, acknowledged that this was not perfect but ruled that this struck the balance between 'a fair protection for the patent proprietor with a reasonable degree of legal certainty for third parties' as required by the Protocol on the interpretation of Article 69 of the European Patents Convention. Lord Hodge and Lord Briggs, on the other hand, preferred the view that the test is whether the alleged infringer subjectively intended to target the patent protected market. Lord Mance, who regarded his comments as 'obiter' agreed the infringement test depended on the objective appearance and characteristics as prepared but left open the possibility that the context may make it obvious that these are not to be taken at face value, stating:

"It may be going too far in favour of generic manufacturers to suggest as an absolute rule that a generic product, prepared, presented and put on the market, must always be viewed in isolation by reference only to its own packaging and instructions, and without regard to the realities or of the market for which it is prepared and into which it is being released."

Indirect infringement

'Indirect infringement' is concerned with the position where a person incurs liability for infringement by knowingly supplying to a primary infringer the means of putting the invention into effect. In the present case, the Supreme Court stated that it was unnecessary to explore in detail what this entails. This case concerned a so-called 'Swiss-type claim', i.e. a claim with the general format:

Use of 'Compound A' for the manufacture of a medicament for the treatment of 'Disease X'

The court decided that the invention is the manufacture of pregabalin for the designated use and not the subsequent use of the product for treating patients. Therefore, there was no indirect infringement. It will be interesting to see how the courts apply this decision to the newer format used in Europe for 2nd medical use claims, i.e.

'Compound A for use in the treatment of Disease X'.

Lord Briggs in his section of the judgement referred to 'Swiss-type' claims as a 'closed class', suggesting that further consideration of infringement of 2nd medical use claims in the new format will be required by the courts.

Sufficiency

The sufficiency requirement is that the 'specification shall disclose the invention in a manner which is clear enough and complete enough for the invention to be performed by the person skilled in the art' [Section 14, UK Patents Act 1977]. This requirement goes to the heart of the 'patent bargain' where the inventor receives a time-limited monopoly in return for disclosing the invention fully to the public. The Supreme Court observed that it had been the contribution of judges to work out the principles of how this provision should be applied to 2nd medical use claims. With a 2nd medical use claim, the skilled man can make the drug product and therefore, he is able to 'practice' the invention. Therefore, if Section 14 is read literally it would allow patents to be obtained on a wholly speculative basis. Thus, the courts have decided, with respect to 2nd medical use claims, that the patentee must also disclose some evidence for regarding this assertion as "plausible".

The Supreme Court regarded this a 'low threshold test'. In the leading judgement Lord Sumption argued that the plausibility had to be satisfied by the disclosure in the specification not from common general knowledge alone. The Supreme Court also stated that this requirement did not require experiments in humans and could be demonstrated in the specification without experimental evidence, if there is no substantial doubt about the theoretical case made for the efficacy of the invention. In the present case the Supreme Court ruled that Claim 1 (directed to pain) and Claim 3 (directed to neuropathic pain) were insufficient since the experimental data provided

did not demonstrate a broad pain indication or a broad use in any neuropathic pain. However, the Court was divided in how the plausibility test should be applied. Lords Sumption, Reed and Briggs found that claims to both peripheral neuropathic pain and central neuropathic pain to be insufficient. However, although Lords Hodge and Mance found the claim to neuropathic pain per se to be insufficient, they found that a claim to peripheral neuropathic pain would be sufficient. Although the Supreme Court envisaged a medical use application could be 'sufficient' with no experimental evidence in the application, in the present case there was not uniform agreement across the Justices as to whether claims in the current case were sufficient for 'peripheral neuropathic pain'. Therefore, this author is of the view that having no experimental evidence should only be considered as a last resort and 'in vitro' studies with a clear link to the claimed disease should be considered to be the minimum necessary to support a 2nd medical use patent filing.

Amendment ('Abuse of Process')

In the decision of the High Court, Mr. Justice Arnold ruled that Claim 3 (neuropathic pain) was insufficient. In response to this, about 3 weeks after the judge had handed down the judgement, Warner Lambert applied to the court to amend Claim 3. The judge refused his discretion to amend on the ground that the amendment would require a further trial and the amendment should have been made before or during the first instance proceedings. The Court of Appeal and Supreme Court were unanimous in upholding the decision, stating that the late amendment would be an 'abuse of process'.

Comment

This is a welcome decision for companies who manufacture generic versions of pharmaceuticals since it, in effect, approves the 'skinny labelling' approach and puts a high degree of importance on the packaging and leaflets when considering infringement of a 2nd medical use patent. However, there was no majority agreement from the Justices on the test for infringement for a medical use claim.

Two of the Justices proposed the 'outward presentation test', two of the Justices disagreed and stated that the intention of the alleged infringer had to be considered and the other Justice broadly supported the 'outward presentation test' but wanted to leave the test open since it may not always be as simple as just looking at the packaging, documentation etc.

Therefore, it appears The Supreme Court has not yet set a precedent on this point. It should also be noted that the case relates to 'Swiss-type' claims and therefore, the present decision may be of limited use when considering the infringement test for the newer medical use language now used in European patent filings.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions